Compare APPS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPS | LBRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 620 | 27 |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 1.0B |
| IPO Year | 2012 | N/A |
| Metric | APPS | LBRX |
|---|---|---|
| Price | $8.09 | $39.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.25 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 2.9M | 303.5K |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $13.40 |
| 52 Week High | $13.60 | $41.33 |
| Indicator | APPS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 73.55 |
| Support Level | $3.85 | $27.40 |
| Resistance Level | $8.28 | N/A |
| Average True Range (ATR) | 0.67 | 2.59 |
| MACD | -0.20 | 0.74 |
| Stochastic Oscillator | 5.94 | 92.15 |
Digital Turbine Inc is an independent mobile growth platform that levels up the landscape for advertisers, publishers, carriers, and device original equipment manufacturers. The Company offers end-to-end products and solutions leveraging proprietary technology to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. In addition, its products and solutions provide monetization opportunities for OEMs, carriers, and application (app or apps) publishers and developers.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.